Advanced searches left 3/3

Metastatic Melanoma Dacarbazine - Crossref

Summarized by Plex Scholar
Last Updated: 03 May 2022

* If you want to update the article please login/register

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

Abstract Background: We were looking to find patient subgroups with differing postprogression overall survival rates and investigating the effect of original treatment assignment and initial postprogression therapy on ppOS. In the BRIM-2, BRIM-3, BRIM-7, and coBRIM studies, a randomized covariates and ppOS were used to model relationships in patients with BRAF V600 mutated metastatic melanoma with progressive disease following treatment with cobimetinib plus vemurafenib monotherapy, or dacarbazine. The longest in patients with normal baseline LDH, stage M1c disease, and ppRx with immunotherapy or targeted therapy was the longest in those with elevated baseline LDH > 2 upper limit of normal compared to median. After PD had better ppOS than those given other medications, patients treated with immunotherapy or targeted therapy, after PD had higher ppOS than those receiving other therapies, there were better ppOS across treatment cohorts, patients treated with immunotherapy or targeted therapy.

Source link: https://doi.org/10.1186/s12967-020-02458-x


A Feasibility Study using Polychemotherapy (Cisplatin + Vindesine + Dacarbazine) plus Interferon-Alpha or Monochemotherapy with Dacarbazine plus Interferon-Alpha in Metastatic Melanoma

Methods Between May 1995 and September 1997, 51 melanoma patients underwent a multicentric trial and were randomly assigned to receive cisplatin + vindesine + DTIC + IFN+ DTIC+ IFN- against DTIC + IFN-. Results In the CVD arm, we received 3 complete responses, 2 partial responses, and 5 stable diseases, as well as two partial responses and 4 steadyizations of disease in the DTIC arm. In order to increase the results, future trials will be conducted associating the CVD regimen with biological response modifiers.

Source link: https://doi.org/10.1177/030089160108700402


Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses

The prognosis of patients with melanoma in a late stage is now improving, but it is still in the minority due to the introduction of molecular targeting drugs against BRAF mutation and immune checkpoint inhibitors. We have used dacarbazine for patients with metastatic mucosal melanoma. However, the effectiveness of DTIC in patients with metastatic mucosal melanoma has been limited. These findings indicate that chemotherapy of DTIC with CP could be a treatment for patients with metastatic mucosal melanoma of nasal cavity and paranasal sinuses that are now have dismal prognosis.

Source link: https://doi.org/10.4137/ccrep.s39851


Combined Carboplatin and Cytosine Arabinoside in Metastatic Melanoma Refractory to Dacarbazine

This is a preliminary review of the effectiveness and toxicity of the combination chemotherapy regimen containing carboplatin and cytosine arabinoside in dacarbazine-resistant metastatic melanoma. Patients were expected to be enrolled in the presence of measurable disease centers, an ECOG rating of 2 or less, a life expectancy of at least two months, and prior dacarbazine therapy. In conclusion, the combination of carboplatin and cytosine arabinoside has limited effectiveness as a reversal therapy in melanoma patients undergoing on dacarbazine chemotherapy.

Source link: https://doi.org/10.1177/030089169508100404


Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

Purpose Uveal melanoma is the most common primary intraocular malignancy in adults with no appropriate systemic therapy option in the metastatic setting. Selumetinib, a long-lived oral, potent, and selective MEK1/2 inhibitor with a short half-life, has demonstrated single-agent action in patients with metastatic uveal melanoma in a randomized phase II trial. Methods Selumetinib In Metastatic Uveal Melanoma's study, patients with metastatic melanoma and no prior systemic therapy were randomly assigned to selumetinib plus dacarbazine or placebo plus dacarbazine. PFS events occurred in the selumetinib plus dacarbazine group, compared to 24 in the placebo plus dacarbazine group; the risk ratio for PFS was 0. 78. Conclusion The combination of selumetinib plus dacarbazine had a tolerable safety profile in patients with metastatic uveal melanoma, but did not significantly raise PFS compared to placebo plus dacarbazine.

Source link: https://doi.org/10.1200/jco.2017.74.1090


Randomized phase II study of the safety and efficacy of a human anti-αv integrin monoclonal antibody (CNTO 95) alone and in combination with dacarbazine in patients with stage IV metastatic melanoma: 12-month results

Patients with Stage IV metastatic melanoma were randomly divided 1:1:1:1 to get 5 or 10 mg/kg CNTO 95, or DTIC + either 10 or placebo are administered intravenously every 3 weeks for eight cycles in the absence of disease progression or unacceptable toxicity. Both CNTO 95+DTIC and placebo-DTIC's median PFS was 75 days, placebo+DTIC was 54 days, and both CNTO 95+DTIC alone arms were 42 days. Patients in the CNTO 95+DTIC group had a higher risk of SD 12 wks in comparison to the other three groups compared to the other three groups. For the 5mg/kg and 10mg/kg arms, the median survival was 11. 0 months, 9. 8 months and 14. 9 months, and 8. 8 months for those in the DTIC control arm. In the placebo+DTIC group, a greater proportion of patients had SAEs than in the 5mg/kg, 10mg/kg, or CNTO 95+DTIC groups.

Source link: https://doi.org/10.1200/jco.2009.27.15_suppl.9029


Long-term survival of patients with metastatic melanoma (MM) treated with dacarbazine (DTIC) or temozolomide (TMZ)

Background: Patients with metastatic melanoma have a poor prognosis, with a median survival of 6 to 9 months. Only a small number of patients live long-term are able to survive long term, but it is unknown if LTS refers to systemic therapy, indolent tumor biology, or host immune factors. Dacarbazine is the only approved chemotherapy for the treatment of MM, according to the manufacturer, but temozolomide has similar safety. There are no details regarding the frequency of complete response after DTIC or TMZ, duration of reaction, and whether LTS occurs in patients who have a CR. We wanted to find all patients with MM treated with either DTIC or TMZ at the BC Cancer Agency, who had LTS, which was the result of chemotherapy administration. Methods: In the BCCA pharmacy database, all patients with MM diagnosed with either DTIC or TMZ from January 1, 1988 to February 1, 2006 were identified. DTIC or TMZ were used in the 18-year review of 397 patients with MM. median age 53; male 67 percent; ocular primary 77 percent; non-pulmonary visceral metastases 38 percent; and TMZ 8. 3%. CR 18%, PR/SD 67%, PD 13% The best response to DTIC or TMZ was a CR 18%, PR/SD 67%, PD 13%. LTS is common in patients with MM treated with either DTIC or TMZ, as shown by the author.

Source link: https://doi.org/10.1200/jco.2009.27.15_suppl.9054


Large Randomized Study of Thymosin α 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic Melanoma

Thymosin 1 is an immunomodulatory polypeptide that increases effector T-cell responses. We investigated the efficacy and safety of combining T1 with dacarbazine and interferon alfa in patients with metastatic melanoma in this large randomized trial. DTIC+IFN-T1, DTIC+IFN-T1; DTIC+IFN-T+T1; DTIC+IFN-T1; DTIC+T1; DTIC+IFN-T1; DTIC+T-T1; DTIC+T1; DTIC+T1 ; DTIC+TTTT+TTT+T+T+T+T+T+T+T+TT+T-T-T+T-T+T+TT+T+T+T+T+T1; DTIC+T+T+T1; DTIC+T-T+TT1 ; DTIC+T1-T1; DTIC+T+T1 +T1 IFFN- In these two arms, ten and twelve tumor responses were recorded in the DTIC+IFN-T1 and DTIC+T1 groups, respectively, versus four in the control group, which was sufficient to reject the null hypothesis that P 0. 05 in these two arms. Patients were given T1 for 9. 4 months compared to 6. 6 months in the control group, with 9. 4 months in the treatment group T1 being 9. 4 months. In patients receiving T1 compared to the control group, an increase in PFS was noticed.

Source link: https://doi.org/10.1200/jco.2009.25.5208


Mismatch repair (MMR) and base excision repair (BER) protein expression correlates with clinical response to dacarbazine (DTIC)/temozolomide (TMZ) therapy of patients with metastatic melanoma

The findings of a study examining the correlation between MGMT, MMR, and BER protein expression in tumor tissue of patients with metastatic melanoma and documented clinical response to chemotherapy are published here. Methods: Frosten tumor tissue was obtained from 17 pts of metastatic melanoma treated with DTIC/TMZ. After two cycles of DTIC/TMZ therapy, Tumors were considered responsive if pts had stable disease, partial response or complete response by RECIST criteria; and intolerant if progressive disease was present. Compared to 1 of 7 R, 7 of 9 S tumors had elevated MLH1 expression as a result of functional MMR : 7 of 9 S tumors had elevated MLH1 expression as compared to 1 of 7 R. Clinical responses were also found to be inversely related to pol-ß expression: 6 of 9 S tumors had low pol-ß levels as compared to 1 of 7 R tumors, but not to 1 of 7 R tumors.

Source link: https://doi.org/10.1200/jco.2006.24.18_suppl.8015


Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients

Background: Sorafenib blocks tumor cell proliferation and angiogenesis by blocking a blockade of several kinases, including Raf, VEGFR-2/-3, and PDGFR-. Sorafenib, whether as a monotherapy or in combination with other agents, was generally well tolerated in Phase I/II trials. Methods: This multi-center, open-label, two-stage, uncontrolled Phase II trial was conducted to determine the primary endpoints of toxicity and tolerability of sorafenib in patients with advanced metastatic melanoma. Oral sorafenib 400 mg/m 2 was administered twice daily with Oral sorafenib 400 mg/m 2 in three week cycles. At this interim end of Stage 1's review, 30 patients with metastatic melanoma had been identified. At 6. 4 months, patients with confirmed PR persist on the study drug. Conclusions: Continuous sorafenib 400 mg tablet is generally well tolerated, and it displays promising preliminary anti-tumor activity in combination with DTIC.

Source link: https://doi.org/10.1200/jco.2006.24.18_suppl.8012

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions